The coverage of Section 781 has been almost entirely about what it restricts. That is understandable, since the restriction is what changes an industry. But the same section writes a protective definition around the rest of the plant, and almost nobody has read it.
If you work in fiber, grain, seed or research, this part is the part that concerns you.
Industrial hemp gets its own definition
Section 781 of Public Law 119-37 does not only amend the hemp definition. It inserts a separate definition of industrial hemp, meaning hemp:
“(A) grown for the use of the stalk of the plant, fiber produced from such a stalk, or any other non-cannabinoid derivative, mixture, preparation, or manufacture of such a stalk;
(B) grown for the use of the whole grain, oil, cake, nut, hull, or any other non-cannabinoid compound, derivative, mixture, preparation, or manufacture of the seeds of such plant;
(C) grown for purposes of producing microgreens or other edible hemp leaf products intended for human consumption… derived from an immature hemp plant…;
(D) that is a plant that does not enter the stream of commerce and is intended to support hemp research at an institution of higher education… or an independent research institute; or
(E) grown for the use of a viable seed…”
The phrase doing the work throughout is “non-cannabinoid”. The statute is drawing a line between the plant as a crop and the plant as a source of intoxicating compounds, and it is protecting the first.
What this means in practice
Hemp textiles, hempcrete, fiber processing, hemp seed oil, hemp protein, hemp hearts and animal feed applications are not what any of the restrictive clauses are reaching for. The milligram cap applies to “final hemp-derived cannabinoid products”. A bag of hemp hearts is not one.
Microgreens and edible hemp leaf get an explicit carve-out, tied to immature plants grown from seed under the total THC threshold. That is a narrow and deliberate provision.
Research plants that never enter commerce are protected, provided they support research at a higher education institution or an independent research institute. That matters more than it sounds, because a total-THC standard with no research exemption would have made a lot of legitimate plant science legally awkward.
The seed clause has teeth in both directions
Viable seed is protected under the industrial hemp definition. But the amended hemp definition separately excludes:
“any viable seeds from a Cannabis sativa L. plant that exceeds a total tetrahydrocannabinols concentration (including tetrahydrocannabinolic acid) of 0.3 percent in the plant on a dry weight basis”
So seed from compliant genetics is fine, and seed from high-THC genetics is not hemp. This closes the route of moving genetics under a hemp label, which had been a real pathway.
Why the terpene question sits on the right side of this line
Terpenes are not cannabinoids. The restrictive clauses are written about tetrahydrocannabinols and about “any other cannabinoids that have similar effects” as a tetrahydrocannabinol. Terpenes are a chemically distinct class and do not meet that description.
Meanwhile the protective definition repeatedly uses the phrase “non-cannabinoid derivative, mixture, preparation, or manufacture” when describing what industrial hemp is grown for. The drafting is consistent: cannabinoids are the concern, everything else is agriculture.
That does not mean terpene products face no regulation. Food, cosmetic, flavor and inhalation uses each have their own frameworks and their own safety questions, and terpene safety is worth taking seriously on its own terms. It means this particular statute is not the thing to worry about.
The unglamorous conclusion
A lot of hemp businesses have spent several years chasing the intoxicating end of the category because it was where the margin was. The part of the industry that stayed with fiber, grain and seed has been comparatively ignored and is comparatively untouched by all of this.
That is not a moral point. It is a note that the crop has more than one commercial identity, and only one of them has a deadline in November.
About this article
Written 20 July 2026 and checked against the statute, the Federal Register and the published papers rather than against secondary coverage. Regulatory positions in this area are moving, so check the date before relying on it. Nothing here is legal, tax or medical advice.
